BioInvent

What BioInvent does

BioInvent International AB is a clinical-stage biotechnology company headquartered in Lund, Sweden, listed on Nasdaq Stockholm under the ticker BINV, that discovers and develops immuno-modulatory antibodies for cancer therapy. The company operates with 101-250 employees and its pipeline is anchored by first-in-class drug candidates targeting novel mechanisms: BI-1808, an anti-TNFR2 antibody for T-cell lymphoma and solid tumors; BI-1206, an anti-FcγRIIB antibody for non-Hodgkin's lymphoma; and BT-001, an armed oncolytic virus co-developed with Transgene. A fourth program, BI-1910 (a pure agonist TNFR2 antibody), is currently paused while resources concentrate on BI-1808. The company also retains a royalty interest in HMI-115, an anti-prolactin receptor antibody licensed to Hope Medicine that entered Phase 3 for endometriosis in 2026.

The company's discovery engine rests on two proprietary technology platforms: F.I.R.S.T™, a screening platform that uses patient material as the foundation to simultaneously identify clinically relevant disease targets and matching antibodies, and n-CoDeR®, a proprietary antibody library generated through phage display technology. BioInvent also operates integrated in-house GMP manufacturing (BioInvent Manufacturing) that has produced clinical drug substance for trials across Europe, the USA, Japan, and Australia since 1988, using single-use technology for more than 25 years. The company has secured FDA Fast Track Designation, FDA Orphan Drug Designation, and EMA Orphan Drug Designation for BI-1808 in CTCL/T-cell lymphoma.

BioInvent's revenue model is partnership- and licensing-driven. Revenue streams include research collaboration fees and license payments from pharmaceutical partners (MSD/Merck, AstraZeneca, Transgene, CASI, Daiichi Sankyo, Mitsubishi Tanabe), milestone payments from out-licensed programs (€1 million from Hope Medicine for HMI-115 Phase 3 initiation), royalty monetizations (up to USD 30 million from XOMA Royalty for mezagitamab), and contract manufacturing revenue. Net sales grew from SEK 44.7 million in 2024 to SEK 226.5 million in 2025 against a net loss of SEK -332.9 million; cash and short-term placements stood at SEK 456.5 million as of Q1 2026, with management stating the company is funded into late Q1 2027.

Name

BioInvent

Legal name

BioInvent International AB

Website

https://bioinvent.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

101–250 employees

Short description

BioInvent International AB is a clinical-stage Swedish biotech company that discovers and develops first-in-class immuno-oncology antibodies for cancer therapy. It serves major pharmaceutical partners through licensing, co-development, clinical supply agreements, and contract GMP manufacturing.

Ownership category

akta.pro rank

Product category

Immuno-oncology antibody therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

Keywords

• Immuno-oncology antibodies
• Clinical-stage biopharmaceuticals
• Antibody drug development
• GMP contract manufacturing
• Cancer immunotherapy pipeline

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Research Collaborations: BioInvent generates revenues from research collaborations with multiple top-tier pharmaceutical companies. The company has license agreements and research partnerships with various pharma companies.
2. Manufacturing Services: The company produces antibodies for third parties in its fully integrated manufacturing unit (BioInvent Manufacturing), generating contract manufacturing revenue since 1988.
3. Milestone Payments: BioInvent receives milestone payments from licensed programs, such as the €1 million milestone payment from Hope Medicine for Phase 3 initiation of HMI-115 in endometriosis.
4. Royalty Revenue: XOMA Royalty acquired royalty and milestone rights for mezagitamab from BioInvent for up to USD 30 million, representing future royalty potential.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

BioInvent is a clinical-stage biopharmaceutical company that discovers and develops immuno-modulatory antibody therapeutics for cancer therapy. It uses its proprietary F.I.R.S.T™ screening platform and n-CoDeR® antibody library to generate drug candidates targeting novel mechanisms such as TNFR2 and FcγRIIB. The company also operates a GMP contract manufacturing business unit (BioInvent Manufacturing) that produces clinical-grade drug substance for third parties.

Product overview

BioInvent is a clinical-stage biotech company that discovers and develops immuno-modulatory antibodies for cancer therapy. The company's product portfolio centers on its proprietary F.I.R.S.T™ technology platform and n-CoDeR® antibody library, which fuel a pipeline of clinical-stage drug candidates. Lead programs include BI-1808 (anti-TNFR2 antibody for T-cell lymphoma and solid tumors) and BI-1206 (anti-FcγRIIB antibody for NHL and solid tumors). Additional candidates include BT-001 (oncolytic virus with Transgene), BI-1910 (TNFR2 agonist, currently paused), and licensed programs like HMI-115 (endometriosis). The company also operates a contract manufacturing business unit (BioInvent Manufacturing) providing GMP antibody production services to external clients.

Differentiator

Problem solved

Functional benefit

Products and services

• BI-1808 A first-in-class anti-TNFR2 monoclonal antibody being developed for T-cell lymphoma and solid tumors. BI-1808 depletes immunosuppressive regulatory T cells and reprograms myeloid cells to unleash CD8+ T cell antitumor immunity. Has received FDA Fast Track Designation, FDA Orphan Drug Designation, and EMA Orphan Drug Designation in CTCL.
• BI-1206 An anti-FcγRIIB antibody in clinical development for non-Hodgkin's lymphoma and solid tumors. BI-1206 blocks FcγRIIB to restore and enhance the activity of rituximab and acalabrutinib, overcoming resistance in relapsed/refractory NHL.
• BT-001 A tumor-targeted oncolytic virus co-developed with Transgene, engineered to express a CTLA-4 inhibitor and GM-CSF for the treatment of solid tumors.
• BI-1910 A pure agonist TNFR2 antibody that directly co-stimulates T and NK cells through partially FcγR-independent mechanisms. Currently paused.
• HMI-115 An anti-prolactin receptor antibody licensed to Hope Medicine for the treatment of moderate to severe endometriosis-associated pain, originally discovered using BioInvent's n-CoDeR® phage display technology.
• BioInvent Manufacturing Contract manufacturing services using in-house GMP facilities, producing drug substance for clinical trials in Europe, the USA, Japan, and Australia. Operated since 1988 with single-use technology.

Quantifiable outcome

• BI-1808 monotherapy achieved 40% ORR including a complete response ongoing at two years, and 93% DCR in advanced CTCL
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Hope MedicinecoreStrategic or Co-development Partner · 27 March 2026Hope Medicine (Nanjing) Co. Ltd. licensed HMI-115 from BioInvent (originally discovered using n-CoDeR® technology under 2008 collaboration with Bayer). Hope Medicine initiated Phase 3 trial triggering €1 million milestone payment to BioInvent. Program was assigned to Hope Medicine in 2019.
• TransgenecoreStrategic or Co-development Partner · 13 October 2025Co-development partnership with Transgene for BT-001, an armed oncolytic virus. Data presented at ESMO 2025 showing encouraging results including tumor shrinkage in both injected and non-injected lesions.
• AstraZenecacoreStrategic or Co-development Partner · 1 February 2024Clinical supply agreement with AstraZeneca for Calquence® (acalabrutinib) used in combination with BI-1206 and rituximab in the triple combination arm for NHL treatment.
• PfizerminorStrategic or Co-development Partner · 26 April 2023Collaboration with Pfizer involving certain antibodies was terminated; Pfizer declined continuation of development for certain antibodies from their collaboration.
• MSD (Merck & Co., Inc.)coreStrategic or Co-development Partner · 1 August 2021Clinical trial collaboration and supply agreement to evaluate BI-1808 in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab). Collaboration ongoing since August 2021 for solid tumors and CTCL studies.
• CASI PharmaceuticalsminorStrategic or Co-development PartnerOngoing collaboration with CASI Pharmaceuticals as one of the company's pharmaceutical partners.
• Daiichi SankyominorStrategic or Co-development PartnerOngoing collaboration with Daiichi Sankyo as one of the company's pharmaceutical partners.
• Mitsubishi TanabeminorStrategic or Co-development PartnerOngoing collaboration with Mitsubishi Tanabe as one of the company's pharmaceutical partners.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Genmab: Copenhagen-based clinical and commercial antibody therapeutics company with proprietary discovery/engineering platforms (e.g., DuoBody, HexaBody) and a broad oncology pipeline. Closely comparable to BioInvent in being a European antibody-focused biotech combining platform-driven discovery with clinical-stage immuno-oncology assets.
• MacroGenics: US clinical-stage biotech developing immuno-oncology antibodies (e.g., margetuximab, enoblituzumab) with multiple pharma partnerships. Directly comparable to BioInvent in pipeline composition (Fc-engineered and immuno-modulatory antibodies), stage, and partnership-driven business model.
• CytomX Therapeutics: Clinical-stage oncology biotech with a proprietary Probody® antibody masking platform. Comparable to BioInvent in using a proprietary antibody-engineering platform to generate differentiated immuno-oncology candidates and in its partnership-heavy business model.
• MorphoSys: Germany-headquartered antibody discovery and development company (now part of Novartis following 2024 acquisition). Highly comparable to BioInvent as a European antibody platform company that translated proprietary technology into clinical oncology assets and pursued pharma partnerships.
• Compass Therapeutics: Clinical-stage biotech developing a portfolio of antibody-based immuno-oncology candidates. Comparable to BioInvent in clinical-stage focus on antibody combinations, partnership-driven development, and platform-supported discovery.

Emerging players

• Pyxis Oncology: Clinical-stage biotech developing antibody-drug conjugates and immuno-oncology antibodies. Comparable in clinical-stage immuno-oncology focus and in leveraging platform-based antibody design for novel tumor-targeting mechanisms.
• Werewolf Therapeutics: Clinical-stage oncology biotech developing conditionally activated immuno-oncology therapeutics. Comparable in clinical-stage immuno-oncology focus and partnership orientation, with adjacent (rather than identical) antibody technology.
• Adagene: Clinical-stage biotech leveraging AI-driven antibody engineering (POWER platforms) for immuno-oncology. Comparable to BioInvent in platform-based antibody discovery targeting novel immuno-oncology mechanisms, though with a more computational discovery angle.
• Crescendo Biologics: UK-based clinical-stage biotech with a proprietary T cell engager (Humabody®) platform built on phage-display-derived human VH domains. Closely comparable to BioInvent's n-CoDeR® in using phage display as a core antibody-discovery engine and in oncology focus.

Broad incumbents

• Lonza Group: Global contract development and manufacturing organization (CDMO) providing mammalian biologics manufacturing services. Comparable to BioInvent's BioInvent Manufacturing business unit, though at vastly greater scale and as a pure-play CDMO rather than an integrated drug developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/48512

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioInvent